ImaRx Provides Update on TUCSON Phase I/II Clinical Trial in Acute Ische...(arly clinical recoverywere higher in the...),Health

Cohort 2

The second dose cohort evaluated two vials of MRX-801. Activity data from subjects in this cohort is currently being collected and will be available in the second quarter of 2008. From a preliminary evaluation of the safety data that have been collected to date, there were a greater number of intracranial hemorrhage events observed in subjects receiving treatment relative to controls.

Upon a review of these data, consultation with the Data and Safety Monitoring Board and review by the TUCSON Steering Committee, the Company has elected to suspend further enrollment in the study and intends to conclude the study at this stage.

According to Garen Manvelian, MD, Chief Medical Officer for ImaRx, "We are very encouraged by the data from Cohort 1 and are pleased to have observed activity with the lowest dose of MRX-801. We have learned what we set out to accomplish through this clinical trial." Dr Manvelian further stated, "It is well known that tPA has an associated risk of bleeding. We believe that the intracranial hemorrhage events, such as those observed in Cohort 2, may be reduced by eliminating tPA in our future SonoLysis(TM) clinical studies in stroke."

Paul Sierzenski, MD, North American Principal Investigator for the TUCSON study, stated, "As an Emergency Physician, I diagnose and treat a significant number of patients who are victims of stroke. Physicians of all specialties recognize the devastating impact this disease has on our patient's lives. ImaRx's SonoLysis therapy employs a fundamentally unique approach to the treatment of ischemic stroke. I am excited about the opportunity to participate in future clinical trials to advance the development o
'/>"/>